Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran

计划入组 20 人 · 首次发布于 2023 年 5 月 24 日

Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.

计划入组 150 人 · 首次发布于 2023 年 7 月 18 日

Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers

计划入组 1 人 · 首次发布于 2012 年 5 月 23 日

TTR gene therapy (transthyretin amyloidosis)

Inotersen(Tegsedi)

Rx

Vutrisiran(Amvuttra)

The Trustee for Weigh Less With Jess Trust

Australia

NATIONAL REHABILITATION CENTER FOR PERSONS WITH DISABILITIES HOSPITAL

Japan

Jiangsu Province Hospital (The First Affiliated Hospital With Nanjing Medical University)

China

Royalty Pharma Acquires $310 Million AMVUTTRA Royalty Interest from Blackstone Life Sciences

EU Approves WAINZUA (Eplontersen) for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

FDA Accepts Alnylam's Vutrisiran sNDA for ATTR Amyloidosis with Cardiomyopathy